Recently, newer HF therapies, such as sodium-glucose co-transporter-2 (SGLT2) inhibitors, have improved outcomes in adults with diabetes mellitus and cancers treated with anthracyclines [119]. Here, SLC5A2 is linked to diabetes mellitus.